Search
Search
About
Log in
Join
Experiences with
Lymphocytic leukemia
Posts
Communities
3,080 public posts
Filter results
Dad actively dying , can't breathe. Horrifying. Need support after today if anyone available to reach out.
His pca never changed but very slightly until of all meds and five weeks of hospice..chronic
lymphocytic
leukemia
presumably from treatment is what's taking his life .
His pca never changed but very slightly until of all meds and five weeks of hospice..chronic
lymphocytic
leukemia
presumably from treatment is what's taking his life .
Daddyishealing
in
Advanced Prostate Cancer
10 months ago
Venetoclax has been added to the Pharmaceutical Benefits Scheme in Australia for use as a retreatment for CLL/SLL
[/i] [i]https://www.pbs.gov.au/medicine/item/11624T-11630D-11639N-11648C[/i] This letter to the ASH publication Blood Advance in August 2022 ([i]"Venetoclax retreatment of patients with chronic
lymphocytic
leukemia
after a previous venetoclax-based regimen")[/i] provides some more information about
[/i] [i]https://www.pbs.gov.au/medicine/item/11624T-11630D-11639N-11648C[/i] This letter to the ASH publication Blood Advance in August 2022 ([i]"Venetoclax retreatment of patients with chronic
lymphocytic
leukemia
after a previous venetoclax-based regimen")[/i] provides some more information about
CLLerinOz
Administrator
in
CLL Support
10 months ago
https://www.patientpower.info/chronic-lymphocytic-leukemia/first-ever-car-t-therapy-approved-for-cll-sll
Promising, but unless I have read it wrong only 20% with complete response. What would be interesting is to know how many responded and for what duration
Promising, but unless I have read it wrong only 20% with complete response. What would be interesting is to know how many responded and for what duration
cartwheels
in
CLL Support
3 months ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Patient Power Presents – Dr. Matthew S Davids: Update on Treatment Studies in Richter’s
Matthews discussing recent data related to treatment studies for Richters Transformation - https://www.patientpower.info/chronic-
lymphocytic
-
leukemia
/asco-update-richters-syndrome?
Matthews discussing recent data related to treatment studies for Richters Transformation - https://www.patientpower.info/chronic-
lymphocytic
-
leukemia
/asco-update-richters-syndrome?
Smakwater
in
CLL Support
1 year ago
Early results of the Pirtobrutinib, Obinituzumab, Venetoclax trial I'm on have just been published
Leukemia
(CLL) or Richter Transformation (RT)[/i] The trial is still recruiting.
Leukemia
(CLL) or Richter Transformation (RT)[/i] The trial is still recruiting.
SeymourB
in
CLL Support
1 month ago
MRD Test
After 14 months on Acalabrutinib and Venetoclax, C91.10 Chronic
lymphocytic
leukemia
of B-cell type not having achieved remission. Looks like I failed. 😷
After 14 months on Acalabrutinib and Venetoclax, C91.10 Chronic
lymphocytic
leukemia
of B-cell type not having achieved remission. Looks like I failed. 😷
Lavinia-Blue
in
CLL Support
1 year ago
LET'S TALK CLL- Patients & Doctors Discuss the Latest Live! SATURDAY, OCTOBER 14, 2023 Virtual program starts at 10am CDT 11am EDT
https://us06web.zoom.us/webinar/register/5216926341361/WN_8BHNtMXZR9Gjf211Nh_lhA - EVENT OVERVIEW Are you ready to dive into the most current information about chronic
lymphocytic
leukemia
(CLL)?
https://us06web.zoom.us/webinar/register/5216926341361/WN_8BHNtMXZR9Gjf211Nh_lhA - EVENT OVERVIEW Are you ready to dive into the most current information about chronic
lymphocytic
leukemia
(CLL)?
lankisterguy
Volunteer
in
CLL Support
8 months ago
Spotlight on CLL - Nicole Lamanna, MD Wednesday May 24, 2023 1:00 PM to 2:30 PM EDT- sponsored by LLS- USA but open to all
. - Len - Nicole Lamanna, MD Director, Chronic
Lymphocytic
Leukemia
Program NewYork-Presbyterian/Columbia University Medical Center New York, NY Wednesday May 24, 2023 1 :00 PM to 2 :30 PM Eastern Time 12 :00 PM to 1 :30 PM Central Time 11 :00 AM to 12 :30 PM Mountain Time 10 :00
. - Len - Nicole Lamanna, MD Director, Chronic
Lymphocytic
Leukemia
Program NewYork-Presbyterian/Columbia University Medical Center New York, NY Wednesday May 24, 2023 1 :00 PM to 2 :30 PM Eastern Time 12 :00 PM to 1 :30 PM Central Time 11 :00 AM to 12 :30 PM Mountain Time 10 :00
lankisterguy
Volunteer
in
CLL Support
1 year ago
Understanding How Biomarkers Help Guide Treatment Decisions for Those with CLL/SLL CLL Society Education On-Demand: Replay
Understanding How Biomarkers Help Guide Treatment Decisions for Those with CLL/SLL CLL Society Education On-Demand: REPLAY below https://youtu.be/E1sc_YT4u_g - [i]Each person who is diagnosed with chronic
lymphocytic
leukemia
or small
lymphocytic
lymphoma (CLL/SLL) has a unique set of genetic biomarkers
Understanding How Biomarkers Help Guide Treatment Decisions for Those with CLL/SLL CLL Society Education On-Demand: REPLAY below https://youtu.be/E1sc_YT4u_g - [i]Each person who is diagnosed with chronic
lymphocytic
leukemia
or small
lymphocytic
lymphoma (CLL/SLL) has a unique set of genetic biomarkers
lankisterguy
Volunteer
in
CLL Support
1 year ago
Beyond the Diagnosis: Surviving and Thriving with CLL / SLL
leukemia
or small
lymphocytic
lymphoma (CLL / SLL) are living longer than ever.
leukemia
or small
lymphocytic
lymphoma (CLL / SLL) are living longer than ever.
lankisterguy
Volunteer
in
CLL Support
10 months ago
Shingrix availability on PBS in Australia from 1 November has been confirmed
shingrix-may-be-available-on-australias-national-immunisation-program-for-those-with-cll-from-1-november-2023 To see our pinned post about general vaccination advice for those with CLL and information about this and other vaccines, go to: https://healthunlocked.com/cllsupport/posts/148546478/vaccinations-for-people-with-chronic-
lymphocytic
-
leukemia
-cll-sll
shingrix-may-be-available-on-australias-national-immunisation-program-for-those-with-cll-from-1-november-2023 To see our pinned post about general vaccination advice for those with CLL and information about this and other vaccines, go to: https://healthunlocked.com/cllsupport/posts/148546478/vaccinations-for-people-with-chronic-
lymphocytic
-
leukemia
-cll-sll
CLLerinOz
Administrator
in
CLL Support
9 months ago
Just 5% of therapies tested in animals end up as as human drugs, new study shows. CLL research has particular challenges due to the TME
[/i] [i]https://theconversation.com/just-5-of-therapies-tested-in-animals-end-up-as-as-human-drugs-new-study-shows-231920[/i] We think of CLL as a leukaemia, but CLL/SLL (Chronic
Lymphocytic
[u]
Leukemia
[/u], Small
Lymphocytic
[u]Lymphoma[/u]), is the most commonly diagnosed adult Non-Hodgins [u]Lymphoma
[/i] [i]https://theconversation.com/just-5-of-therapies-tested-in-animals-end-up-as-as-human-drugs-new-study-shows-231920[/i] We think of CLL as a leukaemia, but CLL/SLL (Chronic
Lymphocytic
[u]
Leukemia
[/u], Small
Lymphocytic
[u]Lymphoma[/u]), is the most commonly diagnosed adult Non-Hodgins [u]Lymphoma
AussieNeil
Partner
in
CLL Support
17 hours ago
Advances in Chronic Lymphocytic Leukemia: A Master Class for the Community Multidisciplinary Team Open Registration April 27 12:00-1:00PM ET
Advances in Chronic
Lymphocytic
Leukemia
: A Master Class for the Community Multidisciplinary Team Live Simulcast | Register now for this interactive CME/CE/CPE-certified workshop to gain expert insight on current best practices and emerging strategies for advances in chronic
lymphocytic
leukemia
Advances in Chronic
Lymphocytic
Leukemia
: A Master Class for the Community Multidisciplinary Team Live Simulcast | Register now for this interactive CME/CE/CPE-certified workshop to gain expert insight on current best practices and emerging strategies for advances in chronic
lymphocytic
leukemia
lankisterguy
Volunteer
in
CLL Support
1 year ago
Progress update - Pirtobrutinib triple trial for treatment naive
leukemia
/small
lymphocytic
leukemia
, at a sensitivity of 0.01% So, after only 4 cycles, we've achieved MRD4 status (<1 CLL cell in 10,000 WBCs) in the blood.
leukemia
/small
lymphocytic
leukemia
, at a sensitivity of 0.01% So, after only 4 cycles, we've achieved MRD4 status (<1 CLL cell in 10,000 WBCs) in the blood.
SeymourB
in
CLL Support
1 year ago
The current status and challenges of CAR-T therapy in CLL
Although CAR-T cells have demonstrated remarkable success in several diseases, including multiple myeloma, acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL), there has been less success with these agents in patients with chronic
lymphocytic
leukemia
(CLL)."
Although CAR-T cells have demonstrated remarkable success in several diseases, including multiple myeloma, acute lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL), there has been less success with these agents in patients with chronic
lymphocytic
leukemia
(CLL)."
Jm954
Administrator
in
CLL Support
1 year ago
Transforming Outcomes in Chronic Lymphocytic Leukemia: Highlights from the ASH 2022 Meeting and Beyond
www.onclive.com/view/btk-inhibitors-in-relapsed-refractory-chronic-
lymphocytic
-
leukemia
https://www.onclive.com/view/head-to-head-trials-of-btki-in-chronic-
lymphocytic
-
leukemia
https://www.onclive.com/view/selecting-the-appropriate-btki-in-chronic-
lymphocytic
-
leukemia
https://www.onclive.com/view/
www.onclive.com/view/btk-inhibitors-in-relapsed-refractory-chronic-
lymphocytic
-
leukemia
https://www.onclive.com/view/head-to-head-trials-of-btki-in-chronic-
lymphocytic
-
leukemia
https://www.onclive.com/view/selecting-the-appropriate-btki-in-chronic-
lymphocytic
-
leukemia
https://www.onclive.com/view/
lankisterguy
Volunteer
in
CLL Support
1 year ago
CAR-T for CLL Hits Goal of Mid-Stage Trial - All patients had progressed on BTK inhibitors & most had failed venetoclax - MedPageToday, 6/12
[/i] [i]A single infusion of the chimeric antigen receptor (CAR) T-cell product lisocabtagene maraleucel (liso-cel; Breyanzi) was shown to induce complete response or remission in patients with relapsed or refractory chronic
lymphocytic
leukemia
(CLL) or small
lymphocytic
lymphoma (SLL), the phase
[/i] [i]A single infusion of the chimeric antigen receptor (CAR) T-cell product lisocabtagene maraleucel (liso-cel; Breyanzi) was shown to induce complete response or remission in patients with relapsed or refractory chronic
lymphocytic
leukemia
(CLL) or small
lymphocytic
lymphoma (SLL), the phase
cujoe
in
CLL Support
1 year ago
Foundation One heme blood test results
This test detected the TCL1A gene, and the report explains this gene is associated with T-prolymphocytic
leukemia
and T-cell chronic
lymphocytic
leukemia
. Also, with Burki lymphoma, in which mutations have been detected in 15% of cases.
This test detected the TCL1A gene, and the report explains this gene is associated with T-prolymphocytic
leukemia
and T-cell chronic
lymphocytic
leukemia
. Also, with Burki lymphoma, in which mutations have been detected in 15% of cases.
Cusube1967
in
CLL Support
1 year ago
MPN Specialists in Uk
Hello My name is Jackie In April of this year I was diagnosed with Intermediate Stage 2 MF. This followed 10 years receiving treatment for ET. My haematologist said he hadn't expected to see this development for another 5+ years. As my father died 3 days after his diagnosis of Acute Myeloid Leukaemia
Hello My name is Jackie In April of this year I was diagnosed with Intermediate Stage 2 MF. This followed 10 years receiving treatment for ET. My haematologist said he hadn't expected to see this development for another 5+ years. As my father died 3 days after his diagnosis of Acute Myeloid Leukaemia
16Gardinia
in
MPN Voice
3 days ago
Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
»The variant allele frequency (VAF) of driver mutations (JAK2, CALR) in myeloproliferative neoplasms is associated with features of advanced disease and complications. Ruxolitinib and interferon were reported to variably reduce the mutant VAF, but the long-term impact of molecular responses (MR) remains
»The variant allele frequency (VAF) of driver mutations (JAK2, CALR) in myeloproliferative neoplasms is associated with features of advanced disease and complications. Ruxolitinib and interferon were reported to variably reduce the mutant VAF, but the long-term impact of molecular responses (MR) remains
Manouche
in
MPN Voice
8 days ago
1
2
3
...
100
Next page
10
20
30
40
50
60
70
80
90
100
Filter results
Clear filters
Posted in
All communities
CLL Support
1933 results
MPN Voice
786 results
Leukaemia CARE
168 results
View top 10 communities
Sort by
Most Relevant
Newest